EU clears Roche’s Ocrevus for MS
Roche’s Ocrevus has been approved for use in Europe to treat adults with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS).
Read More
Tag: CD20-positive
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
